#USA #CARY #Allucent #Hubert Bland #Norman Waters

Allucent Appoints New Leaders in Medical and Infectious Disease Strategy

Allucent, renowned as a global specialty Contract Research Organization (CRO), recently reinforced its leadership team by appointing Hubert Bland as Chief Medical Officer (CMO) and Norman Waters as the Therapeutic Strategy Head of their Infectious Disease Center of Expertise (ACE). This strategic move aims to bolster the company's support for small and mid-sized biopharma enterprises in navigating the intricate pathways of drug development.

Key Appointments and Their Roles

Hubert Bland: Chief Medical Officer

Hubert Bland brings an extensive background with over 30 years in medical affairs, safety governance, and drug development. His previous roles include serving as the vice president and UK country medical director at GSK, where he led the medical affairs organization and ensured compliance with safety regulations. At Allucent, he will direct medical and safety strategies while collaborating closely with sponsors to influence clinical planning and medical decision-making.

Bland’s dual experience on both the side of the sponsor and the CRO equips him with unique insights into the challenges faced during the advancement of new therapies. His leadership is expected to enhance Allucent's ability to fulfill medical, safety, and regulatory requirements.

Norman Waters: Therapeutic Strategy Head for Infectious Disease

With over 25 years of experience in infectious disease research, Norman Waters is positioned to lead the Infectious Disease ACE effectively. His prior achievements include significant contributions during his 31-year tenure in the U.S. Army, where he engaged in various developmental roles, focusing on vaccines and therapeutics for infectious diseases. At Allucent, he is tasked with shaping strategies relating to clinical development across numerous indications and modalities, positioning the company to address both commercial and government-sponsored programs.

Waters' role emphasizes Allucent's commitment to managing the unique challenges of developing infectious disease treatments. He will harness his vast knowledge to guide both private and public sector clients through the complexities involved in clinical development.

Integrated Support for Drug Development

This dual appointment not only enhances Allucent's internal capabilities but reflects its ongoing commitment to delivering specialized therapeutic expertise. The company has structured its ACE model into various domains, including Oncology, Neuroscience, and Immunology, each led by dedicated experts. This integrated approach combines scientific acumen with regulatory and operational proficiency, enabling Allucent to provide tailored support to biopharma companies operating in competitive and challenging environments.

Patrick Phillips, COO of Allucent, emphasized the value of these appointments in offering clients enhanced service. “Both Hubert and Norman bring invaluable insights to help our clients navigate drug development,” he stated. Their extensive backgrounds enable Allucent to maintain its position at the forefront of the industry, particularly for companies requiring advanced support in navigating the complexities of drug development and regulatory challenges.

About Allucent

Founded to address the unique needs of small and mid-sized biopharma companies, Allucent stands out as a tech-enabled CRO specializing in complex scientific processes. The organization combines clinical pharmacology, regulatory strategy, and comprehensive global trial operations, leveraging a team of former regulators and industry leaders. With an impressive track record that includes over 1,100 studies across more than 75 countries, Allucent is poised to help clients accelerate their development timelines while minimizing risk and emphasizing efficiency in reaching critical milestones.

For further information about Allucent and its services, please visit Allucent.com.